In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals, with a price target of $27.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors surrounding Olema Pharmaceuticals’ strategic positioning and potential in the oral SERD market. The recent decision by Pfizer and Arvinas to out-license the commercial rights for vepdegestrant, an oral SERD, highlights a shift in focus that could benefit Olema. Olema’s collaboration with Pfizer on a clinical trial involving a combination of their oral complete estrogen receptor antagonist, palazestrant, and Pfizer’s aermociclib suggests continued interest in the oral SERD space, providing a promising outlook for Olema’s pipeline.
Furthermore, the market dynamics indicate that Pfizer’s interest remains in the oral SERD field, albeit with Olema’s compound rather than Arvinas’. This strategic alignment and potential for advancement in clinical trials bolster the confidence in Olema’s future prospects. Additionally, the financial metrics such as Olema’s cash position and burn rate provide a stable foundation for continued development, supporting the Buy recommendation.
Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and Palvella Therapeutics. According to TipRanks, Slutsky has an average return of 13.6% and a 41.31% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $28.00 price target.